Treatment of typical hemolytic-uremic syndrome: Knowledge gained from analyses of the 2011 E. coli outbreak;Therapie des typischen hämolytisch-urämischen Syndroms: Erkenntnisse aus dem E.-coli-Ausbruch 2011

Internist

Volumn 53, Issue 12, 2012, Pages 1420-1430

  Menne, J ^a   Kielstein, J T ^a   Wenzel, U ^b   Stahl, R A K ^b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Antibiotics; Eculizumab; Immunoadsorption; Plasma exchange; Shiga toxin

Indexed keywords

ARTICLE; DEATH; ENTEROHEMORRHAGIC ESCHERICHIA COLI; EPIDEMIC; ESCHERICHIA COLI INFECTION; GERMANY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MAJOR CLINICAL STUDY; ATTITUDE TO HEALTH; MORTALITY; PLASMAPHERESIS; RISK FACTOR; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; STATISTICS; SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIINFECTIVE AGENT;

ANTI-BACTERIAL AGENTS; DISEASE OUTBREAKS; GERMANY; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEMOLYTIC-UREMIC SYNDROME; HUMANS; PLASMA EXCHANGE; RISK FACTORS; SHIGA-TOXIGENIC ESCHERICHIA COLI; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84878501864     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-012-3107-5     Document Type: Article

References (43)

1. Magnus T, Rother J, Simova O, et al. (2012) The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak. Brain 135:1850-1859
2. Trachtman H, Austin C, Lewinski M, Stahl RAK (2012) Renal and neurological involvement in typical Shiga toxin-associated HUS. Nat Rev Nephrol 8:658-669
3. Weissenborn K, Donnerstag F, Kielstein JT, et al. (2012) Neurologic manifestations of E. coli infection-induced hemolytic-uremic syndrome in adults. Neurology 79:1466-1473
4. Stahl AL, Sartz L, Karpman D (2011) Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117:5503-5513
5. Harendza S (2011) "HUS diary" of a German nephrologist during the current EHEC outbreak in Europe. Kidney Int 80:687-689
6. (o A) (2011) Abschließende Darstellung und Bewertung der epidemiologischen Erkenntnisse im EHEC O104:H4 Ausbruch. Deutschland 2011. http://www.rki.de/DE/Content/InfAZ/E/EHEC/EHEC-Abschlussbericht.pdf?-blob= publicationFile
7. Bielaszewska M, Mellmann A, Zhang W, et al. (2011) Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 11:671-676
8. Rohde H, Qin J, Cui Y, et al. (2011) Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med 365:718-724
9. Rasko DA, Webster DR, Sahl JW, et al. (2011) Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 365:709-717
10. Frank C, Werber D, Cramer JP, et al. (2011) Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany-preliminary report. N Engl J Med 365:1771-1780
11. Hickey CA, Beattie TJ, Cowieson J, et al. (2011) Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome. Arch Pediatr Adolesc Med 165:884-889
12. Kielstein JT, Beutel G, Fleig S, et al. (2012) Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic-uraemic syndrome: an analysis of the German STEC-HUS registry. Nephrol Dial Transplant 27:3807-3815
13. Deutsche Gesellschaft für Nephrologie (DGfN) (2011) Therapeutische Apheresebehandlung bei EHEC assoziiertem HUS. http://www.dgfn.eu/indexphp?eID= tx-nawsecuredl&u=0&file=uploads/media/Apheresebehandlung-bei-EHEC- assoziiertem-HUSpdf&t=1319206713&hash= f151eac68f20e001487b481800ceacfb40991f70
14. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. (2010) Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 25:83-177
15. Te Loo DM, Hinsbergh VW van, Heuvel LP van den, Monnens LA (2001) Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J Am Soc Nephrol 12:800-806
16. Dundas S, Murphy J, Soutar RL, et al. (1999) Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 354:1327-1330
17. Bambauer R, Latza R, Schiel R (2011) Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects. Ther Apher Dial 15:10-19
18. Loirat C, Sonsino E, Hinglais N, et al. (1988) Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 2:279-285
19. Rizzoni G, Claris-Appiani A, Edefonti A, et al. (1988) Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 112:284-290
20. Loos S, Ahlenstiel T, Kranz B, et al. (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753-759
21. Menne J, Nitschke M, Stingele R, et al. (2012) Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 345:e4565
22. Ruggenenti P, Remuzzi G (2011) A German outbreak of haemolytic uraemic syndrome. Lancet 378:1057-1058
23. Greinacher A, Friesecke S, Abel P, et al. (2011) Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial. Lancet 378:1166-1173
24. Combe C, Bui H, Precigout V de, et al. (2011) Immunoadsorption in patients with haemolytic uraemic syndrome. Lancet 379:517-518 (Autorenantwort 518-519)
25. Pietrement C, Bednarek N, Baudouin V, et al. (2012) Immunoadsorption for paediatric post-diarrhoea haemolytic-uraemic syndrome with severe neurological involvement. Clin Kidney J 5:484-485
26. Ashkenazi S, Cleary TG, Lopez E, Pickering LK (1988) Anticytotoxin- neutralizing antibodies in immune globulin preparations: potential use in hemolytic-uremic syndrome. J Pediatr 113:1008-1014
27. Wong CS, Jelacic S, Habeeb RL, et al. (2000) The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930-1936
28. Panos GZ, Betsi GI, Falagas ME (2006) Systematic review: are antibiotics detrimental or beneficial for the treatment of patients with Escherichia coli O157:H7 infection? Aliment Pharmacol Ther 24:731-742
29. Tarr PI, Gordon CA, Chandler WL (2005) Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365:1073-1086
30. Safdar N, Said A, Gangnon RE, Maki DG (2002) Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 288:996-1001
31. Nitschke M, Sayk F, Hartel C, et al. (2012) Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4. JAMA 307:1046-1052
32. Bielaszewska M, Idelevich EA, Zhang W, et al. (2012) Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 56:3277-3282
33. Nurnberger J, Philipp T, Witzke O, et al. (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 360:542-544
34. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al. (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561-2563
35. Tschumi S, Gugger M, Bucher BS, et al. (2011) Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings. Pediatr Nephrol 26:2085-2088
36. Noris M, Remuzzi G (2009) Atypical hemolytic-uremic syndrome. N Engl J Med 361:1676-1687
37. Bell BP, Griffin PM, Lozano P, et al. (1997) Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 100:E12
38. Slutsker L, Ries AA, Maloney K, et al. (1998) A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 177:962-966
39. Cimolai N, Basalyga S, Mah DG, et al. (1994). A continuing assessment of risk factors for the development of Escherichia coli O157:H7-associated hemolytic uremic syndrome. Clin Nephrol 42:85-89
40. Ostroff SM, Kobayashi JM, Lewis JH (1989) Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 262:355-359
41. Pavia AT, Nichols CR, Green DP, et al. (1990) Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr 116:544-551
42. Ikeda K, Ida O, Kimoto K, et al. (1999) Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol 52:357-362
43. Proulx F, Turgeon JP, Delage G, et al. (1992) Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 121:299-303